Michael J. Fox Foundation Annual Review: Advancing Parkinson’s Treatments – A New Era of Hope

The field of Parkinson’s Disease research is experiencing unprecedented progress, fueled by a deeper understanding of the disease’s biology and groundbreaking advancements in biomarkers. These developments are driving the most robust pipeline of PD treatments in history, targeting both the underlying biology and symptoms at all stages of the disease. The Michael J. Fox Foundation summarised its latest efforts in their recent newsletter. Targeting Parkinson’s at Its Core Innovative therapies aim to address the molecular roots of Parkinson’s, with the ultimate goal of slowing, stopping, or even reversing the disease. Among these: - Alpha-synuclein therapies: With at least 15 drugs in development, approaches range from reducing alpha-synuclein clumps to preventing their spread. Notable efforts include Annovis’s oral drug buntanetap, Roche’s antibody prasinezumab, and Vaxxinity’s vaccine — all supported by the Michael J. Fox Foundation (MJFF). - Genetic targeting: Research into LRRK2 and GBA genetic variants linked to PD has advanced rapidly. MJFF has launched the LRRK2 Investigative Therapeutics Exchange (LITE), a $40-million initiative led by renowned researcher Dario Alessi. Promising drugs targeting these genes are in clinical trials, including ambroxol, which may slow disease progression. - Emerging approaches: Novel treatments focus on mitochondrial repair, inflammation reduction, and glucagon-like peptide-1 activators (e.g., Ozempic) to protect neurons. Improving Symptom Management New therapies aim to enhance quality of life by alleviating PD symptoms: - Motor symptoms: Several drugs targeting freezing of gait, “off” periods, and involuntary movements are nearing approval. For example, AbbVie’s levodopa-based infusion pump and Amneal’s oral extended-release carbidopa-levodopa therapy show promise for advanced PD. - Cell replacement and protection: Advances in stem cell-derived therapies, like those from BlueRock Therapeutics, and gene therapies to deliver growth factors are moving into later-stage trials. Non-motor symptoms: Treatments for cognitive changes, apathy, and depression are under investigation, including psilocybin and ketamine. Technology-based solutions, such as wearable devices to manage swallowing difficulties and speech-improvement apps, are also emerging. De-risking to Accelerate Innovation: MJFF employs a “de-risking” strategy to lower barriers for companies developing Parkinson’s treatments. By funding early-stage research, the Foundation encourages biotech and pharmaceutical investment in promising therapies. This approach has led to significant industry acquisitions, such as AbbVie and Merck’s 2024 acquisitions of MJFF-supported partners. This year, MJFF launched a $30-million program to ensure groundbreaking pre-clinical research transitions from the lab to the therapeutic pipeline, further accelerating the path to new treatments. A Transformative Future: With the convergence of biomarker-driven precision medicine and innovative treatments, the Parkinson’s field is poised for transformative change. From targeting the disease’s biology to managing symptoms more effectively, these advances offer hope for improving the lives of millions affected by Parkinson’s worldwide.